NuvaRing® is the trade name for a vaginal contraceptive ring manufactured by Organon, a company now owned by Schering-Plough, Inc. NuvaRing® is the first and only vaginal birth control ring. It was approved by the Food and Drug Administration (FDA) in 2001. Since that time, there have been reports of many serious side effects in users of NuvaRing®, including pulmonary embolism, deep vein thrombosis, strokes, and heart attacks.

 

What is NuvaRing®?

 

NuvaRing® is a vaginal plastic ring that remains in the vagina for three weeks. The ring is removed on the fourth week. During this three-week period, the ring continuously releases two different types of hormones into a woman’s body. These hormones include ethinyl estradiol (synthetic estrogen) and etonogestrel (a progestin or artificial progestagen, another hormone). Etonogestrel is considered a third-generation progestin, which has been associated with a greater risk for developing blood clots than the type of artificial progestagen used in other hormonal birth controls. Etonogestrel is proprietary to Organon, now a subsidiary of Schering-Plough, which is soon to be acquired by Merck, and is used only in NuvaRing® and their implant birth control method, Implanon.

 

NuvaRing® Dangers

 

There are a number of dangerous side effects being reported by women after using NuvaRing® birth control. These side effects include:

• Deep vein thrombosis (blood clots most often occurring in the legs, arms and pelvis)
• Pulmonary embolism (a blood clot in the lungs)
• Strokes
• Heart attack

 

 

NuvaRing® Lawsuits

 

Numerous lawsuits have already been filed by women who have suffered serious side effects while using NuvaRing®. You may also be eligible for compensation. Please contact us to schedule a NuvaRing® lawsuit consultation with the pharmaceutical injury lawyers at Schlichter, Bogard & Denton today. The US District Court in St. Louis is the venue for the multidistrict litigation for Nuvaring®, and Schlichter, Bogard & Denton attorneys have a lead role in handling this litigation.